Portal de Periódicos da CAPES

Carta Produção Nacional Revisado por pares

BIBTEX RIS

In vitro antimicrobial susceptibility of clinical and environmental strains of Burkholderia pseudomallei from Brazil

2013; Elsevier BV; Volume: 42; Issue: 4 Linguagem: Inglês

10.1016/j.ijantimicag.2013.07.001

1872-7913

Tereza de Jesus Pinheiro Gomes Bandeira, Raimunda Sâmia Nogueira Brilhante, Marcos Fábio Gadelha Rocha, Camila Alencar Moreira, Rossana de Aguiar Cordeiro, Joyce Fonteles Ribeiro, Débora de Souza Collares Maia Castelo‐Branco, José Júlio Costa Sidrim,

Burkholderia infections and melioidosis

Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.